BridgeBio Pharma gets FDA priority review for dwarfism drug
Drugmaker BridgeBio Pharma's experimental oral drug infigratinib has been granted priority review by the U.S. Food and Drug Administration (FDA) for treating achondroplasia, the most common form of dwarfism in children. The FDA has set February 4, 2027, as the target decision date. A late-stage study showed children tr